cms

November 13, 2023

Startup PBMs See Growth in Price Transparency A series of startup PBMs are seeing some success signing up health plans by riding the price transparency train. They have even set up their own trade group to differentiate themselves from traditional PBM lobbying efforts. An interesting development, but one that will take time to break the dominance of the three giants, which control about 80% of all the business. (may require subscription) #medicareadvantage #commercial #medicaid #pbms #pricetransparency Link to Article Health Affairs Forefront Blog on FDA Process I am a notable critic of the FDA. I see it as a revolving door agency (FDA to brand PhRMA and back again) and dominated by pressure from the drug industry to approve drugs that are not often ready for launch. In fairness to the FDA, here is a good article on the process and challenges FDA has, including from advocates. (may require subscription)

Read More »

Major Changes in Medicare Advantage Oversight

The Centers for Medicare and Medicaid Services (CMS) have been active this year proposing major new restrictions on Medicare Advantage (MA) plans. Many of the changes are in reaction to provider lobbying efforts on Capitol Hill as well as public outcry over misleading tactics by third-party entities who enroll individuals in the popular senior and disabled plans. Let’s start out with the changes effective January 1, 2024, from the 2024 MA and Part D rule finalized earlier this year.  It is important to note that CMS issued a memo that states that it will enforce the 2024 rule beginning January 1, 2024.  Usually, such rules are enforced through the regular program audit process and it takes a number of years before regulatory changes are rolled into the audit protocols.  That seemed fair as major changes take time for plans to implement.  But in the October 24, 2023, memo issued through

Read More »

Available Now

$30.00